Webinar: Communicating with People with Dementia – Holding Conversations Using the Example of Integrative Validation – with Sabine Seipp

Communicating effectively – but how? As already became clear in the last webinar with Prof. Gabriele Wilz, various barriers can arise when communicating with people with dementia. These hinder exchange and can thus strain the personal relationship with the affected person. Communication with people with dementia can be facilitated...

Communication with People with Dementia – General Guidelines and How to Handle Problematic Situations

Communication with other people is an essential part of our daily lives. However, various barriers arise when communicating with people with dementia, making exchange and related social participation more difficult. Misunderstanding, arguments, anger, and irritation, or even social withdrawal can be the consequences. In the lecture...

Webinar: Communication with People with Dementia – General Tips and Handling Problem Situations – with Prof. Dr. Gabriele Wilz

Communication with other people is an essential part of our daily lives. However, various barriers arise when communicating with people with dementia, making exchange and related social participation more difficult. Misunderstanding, arguments, anger, and irritation, or even social withdrawal can be the consequences. In the lecture...

400 Participants Surveyed for digiDEM Bavaria Dementia Registry

Die Projektphase von digiDEM Bayern startete am 01.01.2021. Seitdem wurden 400 Menschen mit leichten kognitiven Einschränkungen (MCI) und Menschen mit Demenz sowie ihre pflegenden Angehörigen zu ihrer Versorgungssituation befragt. Trotz erschwerter Bedingungen im Rahmen der COVID-19 Pandemie gelang es den digiDEM Forschungspartner*innen in allen sieben bayerischen Regierungsbezirken, zahlreiche Teilnehmende zu …

Urban-rural differences in the diagnosis and treatment of dementia

Studies indicate differences in both the timing of diagnosis and the treatment of people with dementia between urban and rural regions. U.S. researchers wanted to find out how significant these differences are. The background of the study by Rahman and colleagues is that there are disparities in the availability, accessibility, and acceptance...

Controversy over new Alzheimer's drug

A new drug has been approved in the US, sparking a global controversy within Alzheimer's research. This is because 10 out of 11 reviewers rejected the drug for the treatment of Alzheimer's disease. The dementia group of the Cochrane Institute provides a brief overview of the evidence for Aducanumab. For a long time, there was...